S ubfecundity is a key health concern among young adults, with ≈6% to 15% of couples attempting pregnancy in the United States experiencing infertility [1] [2] [3] and, of those who become pregnant, 20% to 30% experiencing a pregnancy loss. 4, 5 Women with a personal history of adverse reproductive events, such as pregnancy loss and preterm birth, are at greater risk for cardiovascular disease later in life, 6, 7 raising the hypothesis that early-stage cardiovascular dysregulation is initiated early in life and may be associated with adverse reproductive events.
Elevated blood pressure levels in young adulthood, particularly diastolic blood pressure (DBP), are associated with a greater risk of developing cardiovascular disease. 8, 9 Although genetics play a role in interindividual variation in blood pressure, many lifestyle and environmental factors influence risk of hypertension, potentially through multiple pathways including inflammation, oxidative stress, and endothelial dysfunction. 10 These same pathways have been associated with adverse reproductive events, through effects on key reproductive processes such as ovulation, implantation, and vascularization of the placenta. [11] [12] [13] [14] Despite a strong rationale for a shared pathology for elevated blood pressure and adverse reproductive events, 8, 9 prior research on preconception hypertension and reproductive outcomes is sparse and inconclusive. 15, 16 To our knowledge, preconception blood pressure, a relatively easy and noninvasive measure of cardiovascular disease risk, has not been studied in relation to reproductive health among women without preexisting cardiovascular disease. To address this research gap, we evaluated the association of preconception and early pregnancy blood pressure with fecundability, pregnancy loss, and live birth in a prospective time-to-pregnancy and pregnancy outcomes cohort.
Methods
Consistent with National Institutes of Health policy, our data can be made available to other researchers. For details, please see http:// grants.nih.gov/grants/policy/data_sharing/ for the National Institutes of Health data sharing policy.
Study Design
This preconception prospective cohort study is set in the EAGeR trial (Effects of Aspirin on Gestation and Reproduction), a randomized clinical trial of low-dose aspirin (LDA) and reproductive outcomes conducted from 2007 to 2011. As previously described, 17 participants were recruited from 6 clinical sites across the United States. At the beginning of the first menstrual cycle of follow-up, participants were assigned to either daily 81-mg aspirin plus folic acid or placebo plus folic acid, which participants continued to take for up to 6 menstrual cycles of attempting pregnancy and throughout pregnancy if pregnancy was achieved. Women were eligible if they were actively trying to conceive and had experienced 1 to 2 prior pregnancy losses and up to 2 prior live births. Additional inclusion criteria were 18 to 40 years of age, regular menstrual cycles of 21 to 42 days, no history of infertility, no major medical problems for which they were currently being treated by a physician (including hypertension and polycystic ovarian syndrome), no known contraindication to aspirin, and no indication for anticoagulant treatment.
During the preconception enrollment visit, participants completed demographic and medical history questionnaires, provided blood and urine samples, and had anthropomorphic measures taken. Follow-up continued for up to 6 cycles of attempting pregnancy and throughout pregnancy for those who became pregnant. The institutional review boards at all participating institutions approved the study protocol, and all participants provided informed consent before data collection. All study procedures were performed in accordance with institutional guidelines and in adherence with the principles of the Declaration of Helsinki.
Preconception blood pressure was measured at enrollment by trained study staff with a sphygmomanometer. Cuff size (small, adult, or large) was determined by arm circumference. Three sequential blood pressure measures were averaged to produce summary systolic blood pressure (SBP) and DBP measures. Mean arterial pressure (MAP) was calculated from SBP and DBP measures using the following formula: MAP=DBP+(1/3×[SBP−DBP]). Blood pressure measures were also captured during regularly scheduled prenatal care visits at 4, 8, 12, 16, 20, 28 , and 36 weeks' gestation. We evaluated blood pressure at 4 weeks' gestation only because later measures were scheduled to occur after the majority of losses had taken place. Blood pressure was modeled continuously in units of 10 mm of mercury (mm Hg).
Pregnancy status was assessed via presence of human chorionic gonadotropin (hCG). Women performed at-home and in-clinic hCG tests at the end of each cycle (Quidel Quickvue; Quidel Corporation, San Diego, CA; sensitive to 25 mIU/mL hCG). In addition, β-hCG was measured in first-morning urines from the last 10 days of the first 2 menstrual cycles during follow-up and on all end of cycle visits to detect pregnancy (catalogue number: 4221-16; Diagnostic Automation, Inc, Calabasas, CA; and catalogue number. R1S0011R; BioVendor, Asheville, NC).
Fecundability, the menstrual cycle-specific probability of pregnancy, was assessed as time-to-pregnancy, the number of menstrual cycles from the beginning of follow-up to either positive hCG test or censoring. Of the 431 participants who did not become pregnant, 318 were censored at the end of follow-up and 113 before the end of follow-up (median, 3; interquartile range, 1-4 cycles).
Assessment of pregnancy loss included both hCG-detected losses and clinically recognized losses. hCG-detected losses were identified either by a positive urine pregnancy test at the clinic followed by absence of clinical signs of pregnancy or by testing of β-hCG in urine samples collected at home on the last 10 days of each woman's first and second cycle of study participation and on spot urine samples collected at all postcycle visits. Clinical losses were identified for participants who had a clinically confirmed pregnancy on ultrasound at ≈6.5 weeks (determined when ultrasound confirmed a gestational sac, molar pregnancy, ectopic pregnancy, or blighted ovum) but later experienced a participant-or clinician-observed loss. Live births included births of a living infant, with complete follow-up data on 1088 participants.
At baseline, participants self-reported age, race (white versus nonwhite), marital status (married, living as married, and other), cigarette smoking (any versus none), parity (any previous live birth versus none), time from last pregnancy to enrollment (≤4, 5-8, 9-12, and >12 months), number of prior pregnancy losses (1 versus 2), and number of cycles attempting pregnancy before enrollment. Height and weight at enrollment were used to calculate body mass index (BMI).
Statistical Analyses
Descriptive statistics were summarized as frequencies and percents, means and SDs, or medians and interquartile ranges. A total of 97 participants were missing information on number of cycles attempting pregnancy before study entry, 8 were missing blood pressure measures, 14 were missing BMI, and 19 were missing time since last pregnancy loss. We addressed missingness through multiple imputation, using chained equations to generate 20 data sets. 18 Fecundability was assessed with a discrete-time survival model and accounted for left-truncation (cycles attempting pregnancy before enrollment) and right censoring. Right censoring was assumed to be noninformative conditional on all variables included in the model. Pregnancy loss was assessed using log-binomial models, weighted by the inverse of probability of pregnancy to account for exclusion of participants who did not become pregnant. Risk of live birth was assessed using log-binomial models. Models were adjusted for treatment assignment, age, BMI, race, marital status, cigarette smoking, parity, and time from last pregnancy loss to enrollment. We additionally investigated the impact of no pregnancy as a competing risk for pregnancy loss and live birth by modeling both the cause-specific and subdistribution hazards for pregnancy loss and live birth. 19 Cause-specific hazards can be interpreted as the instantaneous risk of pregnancy loss and live birth per change in blood pressure but assume that those with competing risks (eg, not achieving pregnancy) will still experience the event of interest (eg, pregnancy loss). Subdistribution hazards can similarly be interpreted as the instantaneous risk of pregnancy loss and live birth but appropriately allow competing events to remove at-risk women from the sample.
To further explore the relationship between blood pressure and pregnancy loss, we conducted several secondary analyses. First, we evaluated hypertension following thresholds from the 2017 guidelines from the American College of Cardiology and the American Heart Association 20 (SBP≥130 mm Hg or DBP≥80 mm Hg for hypertension stage I and SBP≥140 mm Hg or DBP ≥90 mm Hg for hypertension stage II compared with normal blood pressure <120 and <80 mm Hg). Second, we investigated differences by pregnancy loss type (hCG-detected losses versus clinical losses). Third, we evaluated the association of early pregnancy blood pressure with clinical loss for comparison with our findings for preconception blood pressure. Finally, because inflammation and platelet activation are pathways through which blood pressure may be associated with reproductive outcomes, we evaluated randomization to LDA as a potential effect modifier of the association between blood pressure and reproductive outcomes. All analyses were conducted in SAS 9.4 (Cary, NC), and figures were produced in R (Vienna, Austria).
Results
Among the 1228 women enrolled in the EAGeR trial, mean age was 28.7 (SD, 4.8) years, and 95% were white ( Table 1) . The majority was married (92%), had at least some college education (86%), and had a household income >$40 000/y (67%). Mean BMI was 26.3 (SD, 6.5) kg/m 2 . All women had experienced a prior loss (67% with 1 and 33% with 2 losses), and 53% were parous. At baseline, mean SBP was 111.6 (SD, 12.1) mm Hg, and mean DBP was 72.5 (SD, 9.4) mm Hg ( Figure S1 in the online-only Data Supplement). Mean MAP was 85.5 (SD, 9.6) mm Hg. A total of 307 (25.2%) met criteria for hypertension stage I and 53 (4.3%) for hypertension stage II.
Fecundability
A total of 797 (64.9%) participants achieved pregnancy. Mean SBP and DBP were 111.1 (SD, 11.8) mm Hg and 72.1 (SD, 9.1) mm Hg among those who achieved pregnancy and 112.6 (SD, 12.8) mm Hg and 73.2 (SD, 9.7) mm Hg among those who did not achieve pregnancy, respectively. In unadjusted models, higher levels of all blood pressure measures were associated with lower odds of fecundability (fecundability odds ratio, 0.90; 95% confidence interval [CI], 0.83-0.98 per 10 mm Hg MAP; Table 2 ). After adjustment, associations were attenuated (fecundability odds ratio, 0.98; 95% CI, 0.90-1.08 per 10 mm Hg MAP). Adjusting for all covariates except BMI produced effect estimates similar to unadjusted models (fecundability odds ratio, 0.92; 95% CI, 0.84-1.00 per 10 mm Hg MAP), suggesting that BMI was a key explanatory factor in the unadjusted association of blood pressure with fecundability. Findings were similar for the groups assigned to LDA and placebo (Table 3) .
Pregnancy Loss
Of the 797 participants who achieved pregnancy, 188 experienced a loss (23.6%), with 55 hCG-detected losses and 133 clinically recognized losses. Mean SBP and DBP were 112.3 (SD, 12.3) mm Hg and 73.5 (SD, 9.2) mm Hg among those who experienced a loss and 110.7 (SD, 11.6) mm Hg and 71.6 (SD, 9.1) mm Hg among those who had a live birth. In unadjusted models, an increase in all blood pressure measures was Table 2 ). After adjustment, the associations remained (RR, 1.17; 95% CI, 1.02-1.35 per 10 mm Hg MAP). In an alternate competing risks analysis, cause-specific and subdistribution hazards of pregnancy loss were similar to the main findings, with a 10 mm Hg increase in MAP associated with a 14% (95% CI, 0.96-1.35) greater risk of pregnancy loss (Table 4) .
In a secondary analysis, women with blood pressure levels above the threshold for stage I and stage II hypertension had a 15% (95% CI, 0.86-1.55) and 18% (95% CI, 0.65-2.16) greater risk of pregnancy loss compared with women with normal blood pressure. However, as anticipated, small group sizes contributed to imprecise estimates (Table S1 ).
DBP and MAP had a similar pattern of association with both hCG-detected and clinical loss (RR, 1.14; 95% CI, 0.86-1.52 for hCG-detected and RR, 1.20; 95% CI, 1.01-1.42 for clinical loss per 10 mm Hg MAP; Table S2 ). We additionally evaluated the association of blood pressure measured in early pregnancy at a median of 4.4 weeks' gestation (interquartile range, 4.1-7.9; range, 2.0-20.0 weeks' gestation) with clinical loss. Preconception and early pregnancy blood pressure BMI indicates body mass index; CI, confidence interval; and HR, hazards ratio. *Adjusted for treatment assignment, age, BMI, race (white vs nonwhite), marital status (married, living as married, and other), cigarette smoking, parity, and time from last pregnancy loss to enrolment (≤4 mo, 5-8 mo, 9-12 mo, and >12 mo).
were moderately correlated (r=0.49 and r=0.53 for SBP and DBP, respectively), and mean change in SBP and DBP from preconception to early pregnancy was 0.45 (SD, 11.7) mm Hg and 1.39 (SD, 9.37) mm Hg, respectively. Overall, early-pregnancy blood pressure measures showed a similar pattern of association with clinical loss compared with preconception blood pressure measures (RR, 1.18; 95% CI, 1.00-1.38 per 10 mm Hg MAP in early pregnancy; Table S2 ).
Finally, we observed a marginally stronger association of preconception DBP and MAP with risk of pregnancy loss in the placebo group (RR, 1.27; 95% CI, 1.06-1.53 per 10 mm Hg MAP) compared with the LDA group (RR, 1.07; 95% CI, 0.88-1.30 per 10 mm Hg MAP) in adjusted analyses (P-interaction=0.08; Table 3 ).
Live Birth
Of the 1088 participants with complete follow-up, 597 (55.9%) achieved a pregnancy ending in a live birth over the 6 menstrual cycles of observation. In unadjusted models, higher blood pressure measures were associated with lower risk of live birth (RR, 0.91; 95% CI, 0.86-0.96 per 10 mm Hg MAP; Table 2 ). After adjustment, associations were attenuated (RR, 0.96; 95% CI, 0.90-1.02 per 10 mm Hg MAP). In a secondary competing risks analysis, cause-specific and subdistribution hazard ratios were similar to the main findings, with a 10 mm Hg increase in MAP associated with an 8% lower risk of live birth (95% CI, 0.84-1.01 for subdistribution hazard; Table 4 ).
We observed a marginally stronger association of preconception DBP and MAP with risk of live birth in the placebo group (RR, 0.92; 95% CI, 0.84-1.00 per 10 mm Hg MAP) compared with the LDA group (RR, 0.99; 95% CI, 0.92-1.07 per 10 mm Hg MAP) in adjusted analyses (P-interaction=0.07; Table 3 ).
Discussion
The findings from this study are novel in suggesting that both preconception and early pregnancy blood pressure levels are prospectively associated with risk of pregnancy loss among healthy women with 1 to 2 prior pregnancy losses. We observed that a 10 mm Hg increase in preconception DBP and MAP were associated with a 17% and 18% increase in risk of pregnancy loss, respectively. Findings were consistent across type of pregnancy loss (hCG-detected and clinical losses) and were persistent into early pregnancy. We observed no clear associations of preconception blood pressure with fecundability after adjustment for BMI, suggesting that pathways related to BMI, which is strongly related to fecundability, 21 may explain the marginal association of blood pressure with fecundability. These findings suggest that screening and lifestyle interventions targeting maintenance of healthy blood pressure levels among reproductive-aged women may have additional important short-term benefits on reproductive health.
Few prior studies have evaluated the association of preconception hypertension with pregnancy loss. In a prospective cohort of 2940 women attempting pregnancy in Anhui, China, women with self-reported hypertension during preconception had a greater risk of pregnancy loss (RR, 2.27; 95% CI, 1.27-4.04). 15 However, in a matched case-control study among 550 women in Hamadan Province, Iran, a trend was observed between high blood pressure and lower risk of pregnancy loss (odds ratio, 0.42; 95% CI, 0.15-1.16). 16 Prior research has been limited by reliance on healthcare records or self-reported hypertension and including only those with diagnosed hypertension. Similar to the study in Anhui, we observed that higher blood pressure was associated with a greater risk of pregnancy loss, although our population was largely normotensive. As hypertension is less common among young adults, with stage II hypertension affecting ≈11% of women aged 24 to 32 years, 22 differences in blood pressure at subclinical levels may constitute a significant portion of risk related to blood pressure in this group and, therefore, warrants further exploration. Interestingly, DBP was more strongly associated with pregnancy loss than SBP, a finding similar to research on cardiovascular disease end points. For example, the Framingham Heart Study found that DBP is a stronger predictor of coronary heart disease than SBP among adults aged 20 to 49 years (hazard ratio, 1.34; 95% CI, 1.18-1.51 DBP and hazard ratio, 1.14; 95% CI, 1.06-1.24 SBP per 10 mm Hg). 9 Our findings suggest that incrementally higher DBP among young women may be additionally associated with more proximal pathophysiologic processes contributing to risk of pregnancy loss.
Although the cause of pregnancy loss is often unknown, factors related to key reproductive processes, including ovulation and quality of the oocyte, implantation and decidualization of the endometrium, and vascularization of the placenta, may alter risk of pregnancy loss. 23 Our observation of the association of higher blood pressure with higher risk of pregnancy loss among women with a history of loss would support the idea that one or more of these processes may be adversely impacted by higher blood pressure or that the biochemical milieu associated with higher blood pressure contributes to harming these processes. Indeed, the inflammation, oxidative stress, and endothelial dysfunction that partly underlie development of essential hypertension 24 have also been implicated in pregnancy loss. [11] [12] [13] [14] Additionally, thrombotic factors such as enhanced platelet activation associated with increased production of proinflammatory cytokines and endothelial dysfunction in essential hypertension 25 have been found to be greater among women with pregnancy loss, suggesting that an abnormal thrombotic response may be associated with risk of pregnancy loss. 26 Pregnancy loss and other adverse reproductive outcomes may serve as sensitive markers of early-stage progression toward cardiometabolic disease in young adults, and further elucidating the cardiometabolic risk factors for pregnancy loss may help identify early intervention strategies, such as regular physical activity 27 and following a DASHtype (Dietary Approaches to Stop Hypertension) diet, 28 that may be dually associated with a reduction in risk of adverse reproductive outcomes and later development of cardiometabolic disease. Additional research is needed among women with clinically defined hypertension and at risk for pregnancy loss to determine whether antihypertensive pharmacological interventions may be safe and effective in preventing recurrent pregnancy loss.
We did not have sufficient data to evaluate the association of blood pressure with pregnancy loss by type of loss, including loss because of aneuploidy, although it is likely that blood pressure may differentially effect losses caused by different underlying biological mechanisms. 29 This remains an important point for further research in understanding the mechanisms and risk factors for differing causes of pregnancy loss; however, the estimates for overall loss observed in our study have use in clinical practice where loss type is frequently unobserved.
Our study has several strengths and limitations. First, the EAGeR trial is unique in having preconception measures of blood pressure and a gold-standard prospective assessment of fecundability and pregnancy loss, including hCG-detected losses. However, although our study is prospective, we cannot extrapolate whether the association between DBP and pregnancy loss is causal or attributable to common causes. Additionally, as the study is a prospective cohort, differential loss to follow-up is a potential source of bias; however, the similarity of findings between the secondary hazard analyses and our main analyses suggest that this is unlikely to be a major concern. A unique feature of this study was the randomization to LDA. Our observation that the associations between preconception blood pressure and both pregnancy loss and live birth were partially attenuated in the group assigned to LDA may suggest that a pathway responsive to the anticoagulant and anti-inflammatory properties of aspirin partly underlies the relationship between blood pressure and pregnancy loss. However, because we were not adequately powered to observe interactions with LDA, we cannot make unequivocal conclusions. That the associations of DBP and MAP with pregnancy loss and live birth are particularly strong in the placebo group does support the overall findings for an association of preconception blood pressure with pregnancy loss in the general population. However, because our cohort had a history of 1 to 2 prior pregnancy losses, findings should be generalized with caution to those with no history of pregnancy loss. Additionally, our study population was largely white, were mostly moderate-to high-income, and had no preexisting major medical conditions, and future research is needed to confirm whether these findings are generalizable across race/ ethnicity and socioeconomic status and to those with preexisting medical complications such as hypertension and polycystic ovary syndrome.
Perspectives
Although we observed that preconception DBP and MAP were associated with elevated risk of pregnancy loss, our findings do not establish causality, and additional research is needed exploring the physiology underlying this association to suggest potential routes for intervention. Our findings do suggest that preconception blood pressure is a marker of increased risk of pregnancy loss, independent of age, BMI, and other risk factors, and add to the evidence base suggesting that early markers of cardiometabolic risk may be associated with adverse reproductive events. Our findings are particularly important as they describe risk among women with a history of pregnancy loss, who are at higher risk of experiencing a future loss 30 and for whom preventing pregnancy loss is an increased concern. Future research is needed to confirm these findings and explore the potential underlying causes of this relationship, with the goal of identifying physiological pathways amenable to intervention.
